文献速递肝病

受控衰减参数对利用肝脏硬度测量检测纤维化的影响

Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement.
PubMed 文献 · Aliment Pharmacol Ther · 2018-02-15

结果显示,病因特异性肝脏硬度截断值对排除肝硬化非常有用(阴性预测值98%),对排除显著纤维化作用稍弱(阴性预测值70%),CAP可轻度改善后者的解读;即使截断值很高,肝脏硬度测量对确诊纤维化或肝硬化仍不太可靠。

要点

  • 肝脏硬度低于病因特异性截断值对排除肝硬化非常有用,阴性预测值达98%。
  • 对排除显著纤维化作用稍弱,阴性预测值为70%,考虑CAP可轻度改善解读。
  • 即使截断值很高,肝脏硬度测量对确诊纤维化或肝硬化仍不太可靠。

核心结论

  • 肝脏硬度测量值低于病因特异性截断值对排除肝硬化非常有用,对排除显著纤维化作用稍弱。
  • 对于排除显著纤维化,受控衰减参数可轻度改善解读。
  • 即使截断值很高,肝脏硬度测量对确诊纤维化或肝硬化仍不太可靠。

研究设计与样本

  • 本研究为一项关于受控衰减参数的个体患者数据荟萃分析的二次分析。
  • 当前分析的主要排除标准为病因不明、弹性成像测量不可靠以及数据已用于同一研究问题。

主要发现

  • 约登优化截断值仅足以排除肝硬化,阴性预测值为98%。
  • 采用灵敏度和特异度优化截断值时,排除显著纤维化的阴性预测值为70%,考虑CAP可轻度改善。
  • 显著纤维化和肝硬化的阳性预测值分别为68%和55%,尽管肝硬化采用了特异度优化截断值。

关键数值与推荐

  • 病因特异性肝脏硬度截断值用于估算阳性预测值和阴性预测值,采用逻辑回归作为CAP的函数。
  • 约登优化截断值排除肝硬化的阴性预测值为98%。
  • 灵敏度和特异度优化截断值排除显著纤维化的阴性预测值为70%。
  • 显著纤维化的阳性预测值为68%,肝硬化的阳性预测值为55%。

局限性

  • 本文为个体患者数据荟萃分析的二次分析,当前分析排除了病因不明、弹性成像测量不可靠以及数据已用于同一研究问题的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Liver fibrosis is often accompanied by steatosis, particularly in patients with non-alcoholic fatty liver disease (NAFLD), and its non-invasive characterisation is of utmost importance. Vibration-controlled transient elastography is the non-invasive method of choice; however, recent research suggests that steatosis may influence its diagnostic performance. Controlled Attenuation Parameter (CAP) added to transient elastography enables simultaneous assessment of steatosis and fibrosis. AIM: To determine how to use CAP in interpreting liver stiffness measurements. METHODS: This is a secondary analysis of data from an individual patient data meta-analysis on CAP. The main exclusion criteria for the current analysis were unknown aetiology, unreliable elastography measurement and data already used for the same research question. Aetiology-specific liver stiffness measurement cut-offs were determined and used to estimate positive and negative predictive values (PPV/NPV) with logistic regression as functions of CAP. RESULTS: Two thousand and fifty eight patients fulfilled the inclusion criteria (37% women, 18% NAFLD/NASH, 42% HBV, 40% HCV, 51% significant fibrosis ≥ F2). Youden optimised cut-offs were only sufficient for ruling out cirrhosis (NPV of 98%). With sensitivity and specificity-optimised cut-offs, NPV for ruling out significant fibrosis was moderate (70%) and could be improved slightly through consideration of CAP. PPV for significant fibrosis and cirrhosis were 68% and 55% respectively, despite specificity-optimised cut-offs for cirrhosis. CONCLUSIONS: Liver stiffness measurement values below aetiology-specific cut-offs are very useful for ruling out cirrhosis, and to a lesser extent for ruling out significant fibrosis. In the case of the latter, Controlled Attenuation Parameter can improve interpretation slightly. Even if cut-offs are very high, liver stiffness measurements are not very reliable for ruling in fibrosis or cirrhosis.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Karlas T, Petroff D, Sasso M, et al. Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement. Aliment Pharmacol Ther. 2018. PMID: 29446106. doi:10.1111/apt.14529

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。